Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myESMO
One of the reasons why it is so difficult to maintain weight loss is because adipose issue retains an epigenetic memory of obesity after weight loss.
https://www.nature.com/articles/s41586-024-08165-7
1) Our manuscript entitled « Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments” was recently released in Gut
https://gut.bmj.com/content/early/2024/07/25/gutjnl-2024-331956?rss=1
@campani_claudia @CRCordeliers @SRebouissou @GUTJournal_BMJ @TZ_Hirsch @SImbeaud
